Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
18 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to ProMIS Neurosciences Inc.’s names, not what it holds today.
Patents granted
18
18 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 1 in 2024 and none in 2023
Applications published
25
3 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals2
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Amorfix Life Sciences Ltd. a former name
CA, as the owner printed on each patent
7 publishedPROMIS NEUROSCIENCES INC. its own name
named as the applicant on its applications, in CA
15 publishedProMIS Neurosciences, Inc. its own name
CA, as the owner printed on each patent
0 publishedAmorfix Life Sciences Ltd. a former name
named as the applicant on its applications, in CA
3 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Sep 2, 2025 | 12,404,321 | Conformation-specific epitopes in alpha-synuclein, antibodies thereto and methods related thereof | Biotechnology | ProMIS Neurosciences, Inc. |
| Apr 29, 2025 | 12,286,469 | Humanized antibodies binding to amyloid-beta (A-beta) | Pharmaceuticals | ProMIS Neurosciences, Inc. |
| Aug 27, 2024 | 12,071,472 | Methods of reducing toxicity induced by Amyloid beta (A-beta) oligomers using antibodies specific to A-beta oligomers | Pharmaceuticals | ProMIS Neurosciences, Inc. |
| Aug 21, 2018 | 10,053,510 | FasR antibodies and methods of use | Pharmaceuticals | ProMIS Neurosciences, Inc. |
| May 2, 2017 | 9,637,552 | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases | Pharmaceuticals | ProMIS Neurosciences, Inc. |
| Apr 18, 2017 | 9,625,476 | Methods of diagnosing ALS | Analysis of biological materials | ProMIS Neurosciences, Inc. |
| Dec 20, 2016 | 9,523,697 | Detection of pathogenic abeta using an epitope protection assay | Analysis of biological materials | ProMIS Neurosciences, Inc. |
| Mar 29, 2016 | 9,296,819 | Antibodies and conjugates that target misfolded prion protein | Pharmaceuticals | ProMIS Neurosciences, Inc. |
| Sep 9, 2014 | 8,828,389 | Methods of diagnosing ALS | Analysis of biological materials | Amorfix Life Sciences Ltd. |
| Jul 15, 2014 | 8,778,885 | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases | Pharmaceuticals | Amorfix Life Sciences Ltd. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 13, 2025 | 2025/0346655 | CONFORMATION-SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF | Biotechnology | PROMIS NEUROSCIENCES INC. |
| Sep 18, 2025 | 2025/0289877 | Antibodies to Amyloid Beta | Pharmaceuticals | PROMIS NEUROSCIENCES INC. |
| Feb 13, 2025 | 2025/0051428 | ANTIBODIES TO AMYLOID BETA | Pharmaceuticals | PROMIS NEUROSCIENCES INC. |
| Jun 8, 2023 | 2023/0174630 | SINGLE CHAIN ANTIBODIES AND INTRABODIES TO MISFOLDED TDP-43 AND METHODS OF USE | Biotechnology | PROMIS NEUROSCIENCES INC. |
| May 11, 2023 | 2023/0141177 | ANTIBODIES TO MISFOLDED AMYLOID BETA | Pharmaceuticals | PROMIS NEUROSCIENCES INC. |
| Feb 16, 2023 | 2023/0051538 | CONFORMATION-SPECIFIC EPITOPES IN ALPHA-SYNUCLEIN, ANTIBODIES THERETO AND METHODS RELATED THEREOF | Biotechnology | PROMIS NEUROSCIENCES INC. · patent 12,404,321 granted from it |
| Jul 14, 2022 | 2022/0218805 | CONFORMATION-SPECIFIC EPITOPES IN TAU, ANTIBODIES THERETO AND METHODS RELATED THEREOF | Pharmaceuticals | PROMIS NEUROSCIENCES INC. |
| Feb 24, 2022 | 2022/0056118 | ANTIBODIES TO MISFOLDED TDP-43 AND METHODS OF USE | Biotechnology | PROMIS NEUROSCIENCES INC. |
| Feb 11, 2021 | 2021/0038678 | Methods and compositions for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions | Pharmaceuticals | PROMIS NEUROSCIENCES INC. · patent 11,779,629 granted from it |
| Jun 11, 2020 | 2020/0181247 | Antibodies to Amyloid Beta | Pharmaceuticals | PROMIS NEUROSCIENCES INC. · patent 12,286,469 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 2 · Biotechnology 1.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.